DRUG UTILIZATION REVIEW BOARD MEETING
April 15, 2009
205 JEFFERSON STREET
JEFFERSON CITY, MO 65101

Board Members Present
John Newcomer, MD, Chairman
Jennifer Passanise, FNP
Charlene Heyde, RPh
Stacy Mangum, PharmD
Susan Abdel-Rahman, PharmD
Randy Becker, PharmD

Board Members Absent:
Peggy Wanner-Barjenbruch, MD
Joy Gronstedt, DO
David Campbell, M.D.
Joseph Yasso, DO
Sharad Parikh, M.D.
Sandra Bollinger, PharmD

Contractors in Attendance:

Rick Pope, PharmD, First Health Services
Tom Beetem, RPh, Infocrossing
Jennifer Kemp-Cornelius, PhamD, ACS
Mark Roaseau, MD, PharmD, ACS
Sarah Cooper, Pharmacy Intern
Geri Roling, Inforcrossing

MO HealthNet Division Staff Present:
Ian McCaslin, MD, Director
Rhonda Driver, RPh, Director Pharmacy Program
Jay Bryant-Wimp, RPh, Clinical Pharmacist
Allison Lauf, RN
Mary Heet, RN
Tisha McGowan, Unit Supervisor
DJ Johnson, Medicaid Specialist
Lisa Clements, PhD, Clinical Director Psychology Program
Jayne Zemmer, Program Manager
Angela Wilson, Medicaid Specialist
Andrew Haslag, Fiscal Manager
Beth McQuaide, Administrative Assistant
Jackie Hickman, Unit Supervisor
Angela Wilson,, Medicaid Specialist
Julie Trimble, Medicaid Specialist
Terri Mills, Medicaid Specialist
Renee Riley, Medicaid Specialist
Roxanna Halderman, Medicaid Technician
Terri Brondel, Correspondence and Information Specialist

Others Attending

Jeff Himmelberg, GSK
Laura Minnick, Student
Richard Mesquias, Lilly
P. Winigbermuehle, Astra Zeneca
Dave Croft, BMS
Todd Houldsworth, OMJ
Eric Blake, Schering Plough
Debbie King, Amgen
Molly Skelsey, Astra Zeneca
John Stoner, Astra Zeneca
Grant Cale, BMS
Patrick Jensen, Schering Plough
Joe Summers, Takeda
Susan Zalenski, Johnson and Johnson
Chris Wycinowski, Pfizer
Carol Curtis, Astra Zeneca
John Harris, Abbott
Rob Kilo, Pfizer
Phil King, Pfizer
Robyn Schaiff,, Pfizer
John Valenti, Sanofi

Welcome, Introductions and Opening Remarks	Chairman, John Newcomer, M.D. called the meeting to order at 10:00 a.m. A quorum was not established and the Board met as a Committee of the Whole. A follow up conference call will be scheduled to ratify any recommendations made. A folder of correspondence received and responded to during the quarter, pertaining to the agenda topics, was shared with the Board. A copy of this correspondence is available to Board members upon request. Rhonda.Driver, RPh, Director Pharmacy Program introduced Sara Cooper a pharmacy student completing her internship with the Clinical Services Unit.
Minutes Approval	Minutes of the January 2009 meeting were reviewed and approved as submitted.
Pharmacy Program/Budget Update	In the interest of time no slides were presented. Andrew Haslag provided an update on the current budget as well as the status of discussions within the legislature for Fiscal Year 2010. Ms Driver explained how several PDL classes with contracts expiring July 1, 2009, and due for review this quarter, had been given a one time 3 month extension allowing for a third annual review in June. In response to questions from the Board Ms. Driver discussed the carve out of the pharmacy benefit from Managed Care. She noted that effective October 1, 2009 all Managed Care members will receive their pharmacy benefit through the fee-for –service program. This will add about 358,000 lives to the pharmacy program and increase claim volumes about 20%.
Review of Prior Authorization Meeting:	Copies of the agenda and draft minutes, including public hearing, from the March 2009 *Drug Prior Authorization Meeting* were included in the members' meeting packet.
Implementation Schedule	An updated copy of the *Proposed Implementation Schedule for Edits,* including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had been updated with all edits approved at the last quarter's meetings. This schedule may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf
New Drug Review	• **Discussion -** Drug monographs were available for review at http://www.heritage-info.com/mocaidrx for all new products reviewed this quarter (Identified by First Data Bank in October, November and December). A listing of products recommended for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout (see meeting packet) to all attending. Ms. Driver reviewed MHD recommendations. • **Decision –** In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. New Drug recommendations were included in this block vote. (See Roll Call Vote)
Preferred Drug List (PDL)	Products and classes under review this quarter have existing contracts through June 30, 20009.
Antiemetics-Oral	• **Discussion –** Ms. Driver reviewed the criteria document included in the meeting packet. Preferred and non preferred products were reviewed as well as approval and denial criteria. A new product (Sancuso®) addition was noted. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Beta-Adrenergic Long	• **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products

Acting	and approval/denial criteria. No change was recommended for this class. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Beta Adrenergic-Nebulized	• **Discussion –** Ms. Driver reviewed the criteria document pointing out the addition of generic Accuneb to preferred status. • **Decision -** This PDL recommendation was accepted as presented and added to the block vote. (See Roll Call Votes)
Beta Adrenergic-Short Acting	• **Discussion –**Ms. Driver reviewed the criteria document noting Proventil HFA® was recommended for movement to preferred status while Relion Ventolin HFA® was being recommended as non preferred. • **Decision -** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
COPD Anticholinergics	• **Discussion –**Ms. Driver reviewed the criteria document. No change was recommended. • **Decision -** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Hematopoietic Agents	• **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products and approval/denial criteria. Ms. Driver noted the movement of Epogen® for preferred status recommendation and Procrit® to none preferred status. Ms. Driver pointed out the Drug PA Committee recommendation included transparent approval for pediatric use of the non preferred product. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Inhaled Corticosteroids	• **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products and approval/denial criteria. Ms. Driver noted the recommendation included a new product (Alvesco®) addition to non preferred status and the movement of Symbicort® to preferred status. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Insulins	• **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products and approval/denial criteria. No change was recommended for this class. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Long Acting Insulins	• **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products and approval/denial criteria. No change was recommended and all products in this class remain preferred. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Rapid Acting Insulins	• **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products. No change to the current edit was recommended. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Insulin Mix	• **Discussion –** Ms. Driver reviewed the criteria document including preferred and non-preferred products. No change to the current edit was recommended. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Ophthalmic NSAIDS	• **Discussion –** Ms. Driver reviewed the criteria document noting no change to the current edit. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Seditive Hypnotics	• **Discussion –** Ms. Driver summarized the criteria document noting no change to the current edit was recommended. Clinical edit criteria on Rozerem® remains in place. Member's had requested utilization

	information on this product. Ms. Driver shared this information. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Statins	• **Discussion –** Ms. Driver reviewed the criteria document noting significant changes to the current edit. Altoprev® was recommended as a preferred agent; Crestor® and Lipitor® were both recommended for non preferred status. Ms. Driver noted the Drug Prior Authorization Committee had recommended the trial and failure criteria for transparent approval of a non preferred agent be lowered from MHD's recommendation of 2 agents to trial and failure of 1agent. Members were also provided copies of a drug class review completed by Oregon Health and Science University-Drug Effectiveness Review Project (DERP) and a DERP P&T Committee Brief on this class used for the clinical review for the member's information. Substantial discussion surrounding high potency agents ensued. Discussion surrounding secondary prevention targets followed and members asked if the automated system might be used to identify this population. MHD was asked to develop well defined guidelines for the call center for discussion at the follow-up conference call and to consider inferred or diagnoses that would allow automated approval of a non preferred high potency agent. Robyn Schaaf with Pfizer requested the Board consider automatic approval for 80 mg doses. Discussion on how to identify this population ensued. The Board agreed that first appearing statin at 80 mg was a good practice. Molly Skelesy with Astra Zeneca requested that ATP3 guidelines be used when considering what is high risk. Members discussed how these guidelines do not work with a paid claims data base. Ms. Driver reminded that this is a real time edit. Call center wait times and hours of operation were reviewed. • **Decision –** This PDL recommendation was accepted with three clinical criteria arms to address the primary preventions, secondary prevention and a potential high dose approval. MHD will provide data and the board will continue this discussion on the conference call.(See Roll Call Votes)
Triglyceride Lowrig Agents	• **Discussion –** Ms. Driver reviewed the criteria document noting significant changes to the current edit. A new product Trilipix® was introduced to the class and recommended for preferred status. Antara® was recommended for movement to non preferred status while feonfibrate was recommended as a preferred product. A trial and failure of one agent for transparent approval of a non preferred agent was made by the Drug PA Committee and was reflected in the criteria document. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Urinary Tract Antispasmodics	• **Discussion –** Ms. Driver reviewed the criteria document noting no change to the current edit. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Growth Hormones	• **Discussion –** Ms. Driver reviewed the criteria document noting no change to the current edit. Members were reminded that clinical criteria remains in place for this class. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Androgen Hormone Inhibitors	• **Discussion –** Ms. Driver reviewed the criteria document noting no change to the current edit. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Non-Ergot Dopmine Receptor Agonists	• **Discussion –** Ms. Driver reviewed the criteria document noting the addition of Ropinirole (MAC'd) and Requip®XL to preferred agents and Requip® to non preferred status.

	• **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Low Molecular Weight Heprins	• **Discussion –** Ms. Driver reviewed the criteria document noting no change to the current edit. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Skeletal Muscle Relaxants	• **Discussion –** Ms. Driver reviewed the criteria document noting no change to the current edit. Ms. Driver reviewed the clinical criteria including duration of therapy limits. Jay Bryant Wimp, RPh, Clinical Pharmacist provided an update on the quantity limitation criteria and feedback from the provider community including the effect on practice patterns. MHD will provide utilization data this summer. The Board expressed interest in learning where utilization moved once the quantity limitation took effect. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Benzoyl Persoxide/Clindamycin Topical Agents	• **Discussion –** Ms. Driver reviewed the criteria document. No change to the current edit was recommended. Both products in the class remain preferred agents. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Platelet Inhibitor Agents	• **Discussion –** Ms. Driver reviewed the criteria document noting the addition of a new indication for the product Pletal®. • **Decision –** This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
ACS Healthcare Update	Jennifer Kemp-Cornelius, PharmD. ACS Healthcare Systems summarized the current clinical edit for Tramdol®/Ultram ER. Handouts provided claim counts, paid amounts per participant and utilization data. Helpdesk approval/denial statistics were also shared. Dr. Kemp-Cornelius explained at each meeting she would like to pick an edit that is not routinely reviewed each year as she reviewed each of the handouts. The clinical edit for Suboxone® was reviewed as well as the products efficacy, dosing, warnings and comparative costs at the time of the edit implementation. Claim counts, paid amounts per participant utilization and call center approval/denial statistics were provided. Mr. Bryant Wimp noted that Suboxone® was the study project Ms. Cooper had worked on during her internship with MHD and pointed out interesting findings that might be built into the criteria. Members were asked to provide comments on both these edits. Noting today's discussion Dr. Kemp-Cornelius felt utilization data for the Skeletal Muscle Relaxant Class might be a good topic for next meeting.
Preferred Drug List Discussion/Therapeutic Classes	Therapeutic categories to be considered next quarter will be the continuation of the annual review of products with contracts originally expiring June 30, 2009. Manufacturers in these classes agreed to a one time contract extension allowing the Division to reduce the number of classes reviewed at each annual review. A listing of classes/products under review was provided to all attendees. The Division will also post these classes to the Web page http//:www.dss.mo.gov/mhd..
Program Statistics:	
Top 25 Drugs by Cost	Top 25 drug lists for the, 2nd , 3rd and 4thquarters of 2008 and the first two months of 2009 were provided for the Boards' information. These reports were provided by number of claims and amount paid format. Copies were available to all attendees.
Clinical Edit Summary Report	An overview report of the clinical edit and prior authorization request transaction counts for the month of March 2009 was provided for all attending. The report detailed total transaction counts as well has

	information on the outcome (approval or denial) of the request. Discussion surrounding utilization and denial for Lyrica® ensued . Ms Driver noted that most denials are diagnosis driven and most requests filter for clinical review are for off label use.
Call Center Statistics	A handout illustrating pharmacy help desk call center activity was provided for all attending. Statistics for December 2008 were included. Also included for the Boards' information was a CyberAccess™ Report. This report detailed statistics for CyberAccess™ usage from April 2006 through March 2009 and showed how usage has grown overtime and as edits are implemented. Dr. Kemp-Cornelius provided an update on lab data integration into CyberAccess™ stating that discussion with additional laboratories (Quest and LabCor) was on going. She also noted that e-prescribing was now live within the tool but was not yet captured on the reports.
Program Utilization Information	.Mr. Bryant Wimp asked members to send in suggestions for projects as MHD will be hosting several interns this year.
Adjourn	The DUR Board went into Executive Session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call vote) The next meeting is scheduled for July 15, 2009

Roll Call Votes – April 15, 2009

Member	***New Drug And Clinical Edits***	**PDL Edit Recommendations**	**Statins**	**Closed Session**	***Adjourn***
Susan Abdel-Rahman	***Motion***	Yeah	Yeah	**Motion**	Yeah
Randy Beckner	Yeah	** see below*	***Second***	*Yeah*	*Yeah*
Sandra Bollinger	*Absent*	Absent	Absent	Absent	Absent
Jennifer Passanise	**Second**	Yeah	Yeah	**Second**	Yeah
David Campbell	*Absent*	Absent	Absent	Absent	Absent
Joy S. Gronstedt	*Absent*	Absent	Absent	Absent	Absent
Stacy Mangum	*Yeah*	**Motion**	Yeah	Yeah	**Second**
John Newcomer	Yeah	Yeah	**Motion**	Yeah	Yeah
Sharad Parikh	Absent	Absent	Absent	Absent	Absent
Charlene Heyde	Yeah	***Second***	Yeah	Yeah	**Motion**
Peggy Wanner-Barjenbruch	Absent	Absent	Absent	Absent	Absent
Joseph M. Yasso	Absent	Absent	Absent	*Absent*	*Absent*

***Dr. Beckerner abstained from the vote on the following PDL Classes: Oral Antiemetic; Beta Adrenergic Agents Long Acting, Nebulized and Short Acting; Inhaled Corticosteroids;Triglyceride Lowering Agents, Urinary Tract Antispasmodics, Androgen Hormone Inhibiors, Non-Ergot Dopamine Receptor Agonists, Low Molecular Weight Heprins. His vote is recorded as Yeah for all other classes.**

EXECUTIVE SESSION
April 15, 2009

Board Members Present
John Newcomer, MD, Chairman
Jennifer Passanise, FNP
Charlene Heyde, RPh
Stacy Mangum, PharmD
Susan Abdel-Rahman, PharmD
Randy Becker, PharmD

Board Members Absent:
Peggy Wanner-Barjenbruch, MD
Joy Gronstedt, DO
David Campbell, M.D.
Joseph Yasso, DO
Sharad Parikh, M.D.
Sandra Bollinger, PharmD

Contractors in Attendance:

Rick Pope, PharmD, First Health Services
Jennifer Kemp-Cornelius, PhamD, ACS
Mark Roaseau, MD, PharmD, ACS
Sarah Cooper, Pharmacy Intern

MO HealthNet Division Staff Present:

Rhonda Driver, RPh, Director Pharmacy Program
Jay Bryant-Wimp, RPh, Clinical Pharmacist
Allison Lauf, RN
Mary Heet, RN
Tisha McGowan, Unit Supervisor
DJ Johnson, Medicaid Specialist
Lisa Clements, PhD, Clinical Director Psychology Program
Jayne Zemmer, Program Manager
Angela Wilson, Medicaid Specialist
Andrew Haslag, Fiscal Manager
Beth McQuaide, Administrative Assistant
Jackie Hickman, Unit Supervisor
Angela Wilson,, Medicaid Specialist
Julie Trimble, Medicaid Specialist
Terri Mills, Medicaid Specialist
Renee Riley, Medicaid Specialist
Roxanna Halderman, Medicaid Technician
Terri Brondel, Correspondence and Information Specialist

Minutes Review	Minutes of the January Executive Session were approved as submitted
Case Reviews	In the interest of time and due to the large open session agenda no case reviews were presented.
Adjourn	Executive session adjourned. (See role call vote)